Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients...
Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
About this item
Full title
Author / Creator
Publisher
England: Elsevier Limited
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Limited
Subjects
More information
Scope and Contents
Contents
ObjectiveTo evaluate the efficacy, safety and dose response of a novel oral Janus kinase inhibitor, peficitinib (ASP015K), as monotherapy in Japanese patients with moderate to severe rheumatoid arthritis (RA).MethodsIn a 12-week, double-blind study, 281 adult patients with RA with active disease not on concomitant disease-modifying antirheumatic dr...
Alternative Titles
Full title
Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4893099
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4893099
Other Identifiers
ISSN
0003-4967
E-ISSN
1468-2060
DOI
10.1136/annrheumdis-2015-208279
